Trial Profile
A Phase III trial of intravenous efgartigimod for the treatment of immune thrombocytopenia (ITP)
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 14 Jun 2023
Price :
$35
*
At a glance
- Drugs Efgartigimod alfa (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Registrational; Therapeutic Use
- Acronyms ADVANCE
- Sponsors argenx
- 27 Apr 2023 Results of pooled analysis (phase 2 myasthenia gravis, phase 2 open-label in pemphigus, ADAPT, ADVANCE, and ADAPT+) assessing the safety profile of efgartigimod across different IgG-mediated disorders, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
- 13 May 2020 According to argenx media release, company plans to initiate in the first half of 2020.
- 24 Oct 2019 According to argenx media release, company plans to initiate in the 4Q of 2019